Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 18 October 2016 Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion Minister Muyters, Flemish Minister of Work, Economy, Innovation and Sports visits Biocartis on 18 October 2016 to announce the grant Non-regulated information 11 October 2016 AstraZeneca Comparative Study confirms Best-In-Class Status of Idylla™ KRAS Mutation Detection Technology Non-regulated information 7 October 2016 Three Idylla™ Test Performance Studies to be presented at Esmo Oncology Conference Non-regulated information 6 September 2016 Biocartis Announces H1 2016 Results Regulated information 30 August 2016 Biocartis announces 2016 Half-Year Results on 6 September 2016 Regulated information 20 July 2016 Biocartis Attracts EUR 55 Million Non-dilutive Financing Regulated information 13 July 2016 Disclosure of a Transparency Notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Regulated information 21 June 2016 Biocartis launches advanced EGFR Mutation Assay detecting over 50 mutations Important addition to Biocartis’ core oncology menu now covering most known and used oncology biomarkers Non-regulated information 1 June 2016 Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA Non-regulated information 23 May 2016 Study demonstrating Biocartis’ BRAF liquid biopsy assay... Test can predict therapy response over the course of the cancer treatment Non-regulated information Pagination First page « First Previous page ‹‹ … Page 24 Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Next page ›› Last page Last »